Composition for the treatment of IGF-1R expressing cancer
US10858423B2 · kind B2 · utility
1Cited by
11References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 26, 2016 |
| Grant date | Dec 8, 2020 |
| Priority date | — |
| Expiry date | May 8, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.